Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 3614

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3614

License Grant
We executed a sixth amendment agreement with the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, government organization, and K. U. Leuven Research and Development.  This amendment addresses the sale of tenofovir in upper and lower middle income and Gilead Access Program countries.
License Property
Tenofovir disoproxil fumarate (TDF or PMPA[1]), marketed by under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (NtRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people.  Viread (VEER-ee-ad) is for use in combination with other HIV medications for the treatment of HIV-1 infection in adults.

IPSCIO Record ID: 25888

License Grant
We received the exclusive right to manufacture, use and sell the nucleotide compounds covered by these agreements from the Academy of Sciences of the Czech Republic, government organization.
License Property
Viread a drug for treating HIV infection. Viread is a formulation of a nucleotide analogue reverse transcriptase inhibitor, tenofovir DF, dosed as one 300 mg pill, once a day as part of combination therapy to treat HIV infection in adults.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 253

License Grant
Licensor grants Swiss Licensee a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensee Proprietary Rights and Licensees’ part of the Joint Patents.
License Property
The Parties have previously entered into (a) a Development and License Agreement (including its Appendices) dated as of the 1st day of July 1999, as amended by the Amendment to the Development and License Agreement (DLA First Amendment) executed July 12, 2004 and rescinded and voided ab initio on July 12, 2004 by the Rescission of the Amendment to the Development and License Agreement (Rescission) and the Letter of Amendment (DLA Second Amendment) effective September 20, 2005.

Product relates to brand name Fuzeon® in indications other than the treatment of HIV.  Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product.  Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.  The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021

Field of Use
Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, the Licensor's first and only commercial product, Fuzeon (whose generic name is enfuvirtide, originally known as T-20), offers a novel mechanism of action to treat and potentially prevent the transmission of HIV.

IPSCIO Record ID: 6565

License Grant
The Licensor today announced the execution of a License Agreement for elvucitabine, the Company’s nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of both hepatitis B virus (HBV) infection and human immunodeficiency virus (HIV) infection with the Licensee.

The exclusive License grants the Licensee the right, through its Chinese joint venture with Tianjing Institute of Pharmaceutical Research, to clinically develop and commercialize elvucitabine in mainland China, Hong Kong, and Taiwan. In Phase 2 clinical trials elvucitabine has demonstrated to be safe and well tolerated and to be efficacious in both HBV and HIV infected patients. Under the terms of the Agreement, the Licensee, through a subLicense Agreement with its Chinese joint venture, T & T Pharma Co., Ltd., formed with Tianjing Institute of Pharmaceutical Research  will assume all development and regulatory responsibility and associated costs for elvucitabine.

Field of Use
The rights granted apply to the Pharmaceutical Market relating to healthcare.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.